Phase I study of ixabepilone in combination with capecitabine in Japanese patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

被引：1
|
作者：
Watanabe, J.
Horiguchi, J.
Masuda, N.
Aogi, K.
Sato, R.
Tokudome, T.
Peck, R. A.
机构：
[1] Shizuoka Canc Ctr, Shizuoka, Japan
[2] Gunma Univ, Sch Med, Maebashi, Gunma 371, Japan
[3] Natl Hosp Org Osaka Natl Hosp, Osaka, Japan
[4] Natl Hosp Org Shikoku Canc Ctr, Eihme, Japan
[5] Bristol Myers Squibb KK, Tokyo, Japan
[6] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e13095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13095
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
    Vahdat, Linda T.
    Pruitt, Brian
    Fabian, Carol J.
    Rivera, Ragene R.
    Smith, David A.
    Tan-Chiu, Elizabeth
    Wright, Jonathan
    Tan, Antoinette R.
    DaCosta, Noshir A.
    Chuang, Ellen
    Smith, John
    O'Shaughnessy, Joyce
    Shuster, Dale E.
    Meneses, Nicole L.
    Chandrawansa, Kumari
    Fang, Fang
    Cole, Patricia E.
    Ashworth, Simon
    Blum, Joanne L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 2954 - 2961
  • [32] Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
    Kaufman, Peter A.
    Awada, Ahmad
    Twelves, Chris
    Yelle, Louise
    Perez, Edith A.
    Velikova, Galina
    Olivo, Martin S.
    He, Yi
    Dutcus, Corina E.
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 594 - U202
  • [33] Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.
    Aapro, Matti S.
    Demidchik, Yuri
    Bondarenko, Igor
    Siedakov, Igor
    Sakaeva, Dina
    Krishnamurthy, S.
    Roman, Laslo
    Lebedeva, Liudmila
    Mefti, Fawzia
    Ponomarova, Olga
    Bachelot, Thomas Denis
    Lytvyn, Lryna
    Delaloge, Suzette
    Kupp, Anita
    Karchmit, Yauheniya
    Bougnoux, Philippe
    Campone, Mario
    Martin, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Vahdat, L. T.
    Vrdoljak, E.
    Gomez, H.
    Li, R. K.
    Thomas, E.
    Bosserman, L. D.
    Sparano, J. A.
    Baselga, J.
    Mukhopadhyay, P.
    Valero, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Sunela, Kaisa
    Lehtinen, Ilari
    Joensuu, Heikki
    Sjostrom-Mattson, Johanna
    CLINICAL BREAST CANCER, 2006, 7 (05) : 401 - 405
  • [36] Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine
    Perez, Edith A.
    Lerzo, Guillermo
    Pivot, Xavier
    Thomas, Eva
    Vahdat, Linda
    Bosserman, Linda
    Viens, Patrice
    Cai, Can
    Mullaney, Brian
    Peck, Ronald
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3407 - 3414
  • [37] Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan
    Aogi, Kenjiro
    Rai, Yoshiaki
    Ito, Yoshinori
    Masuda, Norikazu
    Watanabe, Junichiro
    Horiguchi, Jun
    Tokudome, Takuto
    Takashima, Shigemitsu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1427 - 1433
  • [38] Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan
    Kenjiro Aogi
    Yoshiaki Rai
    Yoshinori Ito
    Norikazu Masuda
    Junichiro Watanabe
    Jun Horiguchi
    Takuto Tokudome
    Shigemitsu Takashima
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1427 - 1433
  • [39] A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
    Schmid, P.
    Kuehnhardt, D.
    Kiewe, P.
    Lehenbauer-Dehm, S.
    Schippinger, W.
    Greil, R.
    Lange, W.
    Preiss, J.
    Niederle, N.
    Brossart, P.
    Freier, W.
    Kuemmel, S.
    de Velde, H. Van
    Regierer, A.
    Possinger, K.
    ANNALS OF ONCOLOGY, 2008, 19 (05) : 871 - 876
  • [40] Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer
    Petit, Thierry
    Benider, Abdellatif
    Yovine, Alejandro
    Bougnoux, Philippe
    Spaeth, Dominique
    Maindrault-Goebel, Frederique
    Serin, Daniel
    Tigaud, Jean-Dominique
    Eymard, Jean Christophe
    Simon, Helene
    Bertaux, Brigitte
    Brienza, Silvano
    Cvitkovic, Esteban
    ANTI-CANCER DRUGS, 2006, 17 (03) : 337 - 343
12345